#syt510 — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #syt510, aggregated by home.social.
-
DATE: May 20, 2026 at 09:49AM
SOURCE: PSYCHIATRIC TIMESDirect article link at end of text block below.
Synendos Therapeutics has initiated dosing in a phase 2 trial of SYT-510, a first-in-class endocannabinoid modulator, aiming to ease generalized anxiety disorder symptoms with improved safety and adherence. @synendos
https://t.co/J7IuDAs5XiHere are any URLs found in the article text:
Articles can be found by scrolling down the page at Articles can be found at https://www.psychiatrictimes.com/news".
-------------------------------------------------
DAILY EMAIL DIGEST: Email [email protected] -- no subject or message needed.
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
NYU Information for Practice puts out 400-500 good quality health-related research posts per week but its too much for many people, so that bot is limited to just subscribers. You can read it or subscribe at @PsychResearchBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #psychotherapist #SynendosTherapeutics #SYT510 #EndocannabinoidModulator #GeneralizedAnxiety #Phase2Trial
-
DATE: May 20, 2026 at 09:49AM
SOURCE: PSYCHIATRIC TIMESDirect article link at end of text block below.
Synendos Therapeutics has initiated dosing in a phase 2 trial of SYT-510, a first-in-class endocannabinoid modulator, aiming to ease generalized anxiety disorder symptoms with improved safety and adherence. @synendos
https://t.co/J7IuDAs5XiHere are any URLs found in the article text:
Articles can be found by scrolling down the page at Articles can be found at https://www.psychiatrictimes.com/news".
-------------------------------------------------
DAILY EMAIL DIGEST: Email [email protected] -- no subject or message needed.
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
NYU Information for Practice puts out 400-500 good quality health-related research posts per week but its too much for many people, so that bot is limited to just subscribers. You can read it or subscribe at @PsychResearchBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #psychotherapist #SynendosTherapeutics #SYT510 #EndocannabinoidModulator #GeneralizedAnxiety #Phase2Trial
-
DATE: May 20, 2026 at 09:49AM
SOURCE: PSYCHIATRIC TIMESDirect article link at end of text block below.
Synendos Therapeutics has initiated dosing in a phase 2 trial of SYT-510, a first-in-class endocannabinoid modulator, aiming to ease generalized anxiety disorder symptoms with improved safety and adherence. @synendos
https://t.co/J7IuDAs5XiHere are any URLs found in the article text:
Articles can be found by scrolling down the page at Articles can be found at https://www.psychiatrictimes.com/news".
-------------------------------------------------
DAILY EMAIL DIGEST: Email [email protected] -- no subject or message needed.
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
NYU Information for Practice puts out 400-500 good quality health-related research posts per week but its too much for many people, so that bot is limited to just subscribers. You can read it or subscribe at @PsychResearchBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #psychotherapist #SynendosTherapeutics #SYT510 #EndocannabinoidModulator #GeneralizedAnxiety #Phase2Trial